LMLeloup Manon

Leloup Manon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leloup Manon has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Social Media–Based Professional Intervention vs Resource Provision for Youth With Suicidal Ideation or Behavior: Protocol for a Randomized Controlled Trial

    by Margot Morgiève, Leloup Manon, Anne-Christine Lesniak, Laurine Rougegrez, Nathalie Rigbourg, Vincent Jardon, Marielle Wathelet, Anne-Laure Demarty, Karim Dahache, Alain Duhamel, et al.

    Background: Despite high prevalence of suicidal ideation and behavior, adolescents and young adults often underuse mental health services due to both structural and personal barriers. Simultaneously, massive social media (SM) expansion has introduced new mental health threats, while also creating vital spaces where adolescents and young adults can express psychological distress, seek support, and access mental health information. Designed as a bridge to care and a counterbalance to digital risks, the Équipe en Ligne de Prévention du Suicide (ELIOS) project connects adolescents and young adults with suicidal ideation or behaviors with a team of professionally trained web clinicians (nurses or psychologists supervised by a psychiatrist) through SM platforms. ELIOS is currently being evaluated within the Online Referral and Intervention to Prevent Adolescent and Young Adult Suicide (ORIAS) trial to assess its efficacy. Objective: We assessed the ELIOS system’s efficacy over simple resource provision for adolescents and young adults with suicidal ideation or behaviors. Methods: ORIAS is a single-center, open-label, 2-arm randomized controlled trial with balanced parallel groups. It will recruit 386 participants aged 18-25 years who spontaneously reach out via the ELIOS Facebook Messenger account with recent suicidal ideation. Eligible adolescents and young adults are randomized to receive either the ELIOS intervention or conventional mental health resources (control group). The ELIOS intervention consists of web-clinicians offering initial support, risk evaluation, counseling, and progressive referral to mental health care. The primary endpoint is the reduction in suicidal ideation intensity at 3 months, measured using the Columbia Suicide Severity Rating Scale. Secondary endpoints include suicide attempts, use of health care services, psychological distress, attitudes toward help-seeking, participant satisfaction, and usage metrics of the intervention at 3 months. The primary endpoint will be compared between the 2 study arms using a constrained longitudinal data analysis model. Secondary endpoints assessed at 3 months will be compared between groups using logistic regression models for binary variables and analysis of covariance for continuous variables. Results: The ORIAS study was funded in November 2018, and data collection began in October 2022. As of December 2025, 375 participants had been recruited. Recruitment is expected to conclude in April 2026. Data analysis will be conducted between April and December 2026, with the first publication anticipated in early 2027. Conclusions: ELIOS is the first suicide prevention system embedded directly within the SM environment and daily digital practices of adolescents and young adults. By offering easy, personalized, and timely access to professional help, ELIOS can address help-seeking barriers and reduce suicidality. While the ORIAS trial highlights the inherent challenges of conducting traditional interventional research within dynamic SM settings, it is poised to generate high-quality evidence on the feasibility, acceptability, and effectiveness of digital suicide prevention interventions. These findings could inform and support the broader integration of similar models within public health systems. Trial Registration: ClinicalTrials.gov NCT04642157; https://clinicaltrials.gov/study/NCT04642157 International Registered Report Identifier (IRRID): DERR1-10.2196/83303

  • “You feel like you’re not alone ”: Exploring a sociotechnical assembly in suicide prevention

    by Manon Leloup, Charles-Edouard Notredame, Jonathan Dubois, Philippe Courtet, Margot Morgiève

    Suicidal ideation is highly dynamic and can rapidly escalate to suicide attempts. Traditional clinical assessment tools rely on retrospective, one-off evaluations, limiting their effectiveness in timely intervention and individual prevention. Digital technologies offer promising alternatives by enabling real-time, context-sensitive assessments and interventions. In response to this potential, a multidisciplinary French team developed EMMA—a smartphone application designed to assess and help prevent suicide directly from an individual’s pocket, as part of a clinical trial. Drawing on new materialist and sociomaterial perspectives, this study aims to explore how the use of EMMA reconfigures relationships and practices within the emerging paradigm of digital suicide prevention. Semi-structured interviews were conducted with individuals experiencing severe suicidal ideation, all of whom participated in the clinical trial and used EMMA over a 6-month period. The goal was to capture their subjective experiences and engagement with the digital tool. Participants initially engaged with EMMA as a source of support during a vulnerable post-hospitalization period, perceiving it as an extension of care. Use was most intense in the early weeks, then declined as their condition improved. While EMMA enabled self-reflection and awareness of emotional patterns, it also elicited ambivalent responses—some found it comforting, others intrusive or overwhelming. The app reshaped connections not only to the self but also to relatives and the healthcare system, acting as a relational interface within a broader network of care. Overall, the findings suggest that using EMMA involved forms of digital intimacy within a sociotechnical assemblage, engaging in a complex feedback loop involving the tool, themselves, their relatives, and the healthcare system. This study highlights that innovation in suicide prevention does not reside solely in technological design, but emerges through socio-material practices and the ways digital tools become entangled with lived experience and care relationships.

  • Open Access

    Social Media–Based Professional Intervention vs Resource Provision for Youth With Suicidal Ideation or Behavior: Protocol for a Randomized Controlled Trial (Preprint)

    by Margot Morgiève, Leloup Manon, Anne-Christine Lesniak, Laurine Rougegrez, Nathalie Rigbourg, Vincent Jardon, Marielle Wathelet, Anne-Laure Demarty, Karim Dahache, Alain Duhamel, et al.

    BACKGROUND Despite high prevalence of suicidal ideation and behavior, adolescents and young adults often underuse mental health services due to both structural and personal barriers. Simultaneously, massive social media (SM) expansion has introduced new mental health threats, while also creating vital spaces where adolescents and young adults can express psychological distress, seek support, and access mental health information. Designed as a bridge to care and a counterbalance to digital risks, the Équipe en Ligne de Prévention du Suicide (ELIOS) project connects adolescents and young adults with suicidal ideation or behaviors with a team of professionally trained web clinicians (nurses or psychologists supervised by a psychiatrist) through SM platforms. ELIOS is currently being evaluated within the Online Referral and Intervention to Prevent Adolescent and Young Adult Suicide (ORIAS) trial to assess its efficacy. OBJECTIVE We assessed the ELIOS system’s efficacy over simple resource provision for adolescents and young adults with suicidal ideation or behaviors. METHODS ORIAS is a single-center, open-label, 2-arm randomized controlled trial with balanced parallel groups. It will recruit 386 participants aged 18-25 years who spontaneously reach out via the ELIOS Facebook Messenger account with recent suicidal ideation. Eligible adolescents and young adults are randomized to receive either the ELIOS intervention or conventional mental health resources (control group). The ELIOS intervention consists of web-clinicians offering initial support, risk evaluation, counseling, and progressive referral to mental health care. The primary endpoint is the reduction in suicidal ideation intensity at 3 months, measured using the Columbia Suicide Severity Rating Scale. Secondary endpoints include suicide attempts, use of health care services, psychological distress, attitudes toward help-seeking, participant satisfaction, and usage metrics of the intervention at 3 months. The primary endpoint will be compared between the 2 study arms using a constrained longitudinal data analysis model. Secondary endpoints assessed at 3 months will be compared between groups using logistic regression models for binary variables and analysis of covariance for continuous variables. RESULTS The ORIAS study was funded in November 2018, and data collection began in October 2022. As of December 2025, 375 participants had been recruited. Recruitment is expected to conclude in April 2026. Data analysis will be conducted between April and December 2026, with the first publication anticipated in early 2027. CONCLUSIONS ELIOS is the first suicide prevention system embedded directly within the SM environment and daily digital practices of adolescents and young adults. By offering easy, personalized, and timely access to professional help, ELIOS can address help-seeking barriers and reduce suicidality. While the ORIAS trial highlights the inherent challenges of conducting traditional interventional research within dynamic SM settings, it is poised to generate high-quality evidence on the feasibility, acceptability, and effectiveness of digital suicide prevention interventions. These findings could inform and support the broader integration of similar models within public health systems. CLINICALTRIAL ClinicalTrials.gov NCT04642157; https://clinicaltrials.gov/study/NCT04642157 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/83303